PB 41 of 2024
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 4)
National Health Act 1953
___________________________________________________________________________
I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 98C(1) of the National Health Act 1953.
Dated 29 April 2024
NIKOLAI TSYGANOV
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
1 Name
(1) This instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 4).
(2) This instrument may also be cited as PB 41 of 2024.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 May 2024 | 1 May 2024 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 98C(1) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)
[1] Schedule 1, entry for Cefalexin
omit:
Cefalexin | Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL (s19A) |
[2] Schedule 1, entry for Cefuroxime
omit:
Cefuroxime | Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL |
[3] Schedule 4, entry for Cefalexin
omit:
Cefalexin | Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL (s19A) |
[4] Schedule 4, entry for Cefuroxime
omit:
Cefuroxime | Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL |